Compare FAF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAF | MIRM |
|---|---|---|
| Founded | 1889 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 2009 | 2019 |
| Metric | FAF | MIRM |
|---|---|---|
| Price | $63.42 | $95.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $79.00 | ★ $115.33 |
| AVG Volume (30 Days) | ★ 1.0M | 788.7K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ 376.19 | 74.59 |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $7,452,200,000.00 | $19,138,000.00 |
| Revenue This Year | $8.08 | $26.22 |
| Revenue Next Year | $5.46 | $22.04 |
| P/E Ratio | $10.61 | ★ N/A |
| Revenue Growth | ★ 21.61 | N/A |
| 52 Week Low | $53.95 | $38.22 |
| 52 Week High | $71.47 | $109.28 |
| Indicator | FAF | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 52.92 |
| Support Level | $61.26 | $85.35 |
| Resistance Level | $63.79 | $98.03 |
| Average True Range (ATR) | 1.40 | 3.62 |
| MACD | 0.61 | 0.46 |
| Stochastic Oscillator | 88.59 | 69.11 |
First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.